First‐Line Treatment Patterns and Clinical Outcomes in Patients With HER2‐Positive and Hormone Receptor‐Positive Metastatic Breast Cancer From registHER. (7th May 2013)

• Record Type: Journal Article
• Authors: Tripathy, Debu; Kaufman, Peter A.; Brufsky, Adam M.; Mayer, Musa; Yood, Marianne Ulcickas; Yoo, Bongin; Quah, Cheng; Yardley, Denise; Rugo, Hope S.
• Is Part Of: Oncologist. Volume 18:Number 5(2013)
• Page Start: 501
• Page End: 510
• Publication Date: 2013-05-07
• Subjects: HER2 -- Hormone receptor -- Treatment -- Breast cancer -- Metastatic -- Trastuzumab; Oncology -- Periodicals; Tumors -- Periodicals; Cancérologie -- Périodiques; Tumeurs -- Périodiques; Oncology; Tumors; Neoplasms; Electronic journals; Periodicals; Periodicals; 616.994
• DOI: 10.1634/theoncologist.2012-0414
• Languages: English
• ISSNs: 1083-7159

Abstract

Abstract : Background: Limited data are available describing the natural history of patients with HER2‐positive and hormone receptor (HR)‐positive metastatic breast cancer (MBC). We examined first‐line treatment patterns and clinical outcomes in patients with HER2‐positive, HR‐positive MBC in a real‐world setting. Methods: registHER is a prospective, observational cohort of 1, 023 patients with HER2‐positive MBC diagnosed within 6 months of enrollment and followed until death, disenrollment, or June 2009 (median follow‐up time: 27 months). Demographics, first‐line treatment patterns, and clinical outcomes were examined for 530 HER2‐positive, HR‐positive patients. Progression‐free survival (PFS) and overall survival (OS) times were examined. Multivariate analyses adjusted for baseline demographic and prognostic factors. Results: HER2‐positive, HR‐positive patients receiving first‐line trastuzumab plus hormonal therapy had significantly longer PFS times than patients who received hormonal therapy only (13.8 vs. 4.8 months; adjusted hazard ratio [HR]: 0.37, 95% confidence interval [CI]: 0.22–0.60); a nonsignificant reduction in OS time was observed (adjusted HR: 0.55, 95% CI: 0.27–1.14). Compared with patients who received first‐line trastuzumab plus chemotherapy, patients who received first‐line trastuzumab plus chemotherapy and hormonal therapy had longer median PFS times (20.4 months vs. 9.5 months; adjusted HR: 0.53, 95% CI: 0.42–0.68); a statistically significant reduction in risk of death was observed (adjusted HR: 0.50, 95% CI: 0.36–0.70). Sequential use of chemotherapy and hormonal therapy was associated with improved OS times when compared with concurrent use (adjusted PFS HR: 0.81, 95% CI: 0.54–1.21; adjusted OS HR: 0.48, 95% CI: 0.26–0.89). Conclusions: These real‐world data in patients with HER2‐positive/HR‐positive MBC provide evidence that, with or without chemotherapy, dual targeting of HRs and HER2 receptors is associated with significantly prolonged PFS and OS times. Abstract : This study examined first‐line treatment patterns and clinical outcomes in patients with HER2‐positive, hormone receptor (HR)‐positive metastatic breast cancer in a real‐world setting. With or without chemotherapy, dual targeting of HRs and HER2 receptors was found to be associated with significantly prolonged progression‐free survival and overall survival times.